Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Luye Pharma Group (2186) Stock Price & Analysis

3 Followers

2186 Stock Chart & Stats

HK$1.69HK$0.01(0.30%)
At close: 4:00 PM GMT+8
HK$1.6HK$1.8HK$2Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 1.66 - HKD 1.69
52-Week Range
HKD 1.55 - HKD 3.25
Previous Close
HKD 1.68
Volume
N/A
Average Volume (3M)
18.21M
Market Cap
HKD 6.60B
Enterprise Value
HKD 9.44B
Total Cash (Recent Filing)
HKD 10.76B
Total Debt (Recent Filing)
HKD 12.54B
Price to Earnings (P/E)
8.3
Beta
1.05
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
0.07
Last Dividend Ex-Date
Jun 29, 2020
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong And Durable Operating Margins

High gross, EBIT, and EBITDA margins indicate meaningful product economics and operating discipline in the current portfolio. If maintained, this profitability provides resources for research, commercialization, and lifecycle management while offering some protection against competitive pricing pressure.

Improving Balance-sheet Leverage

Lower leverage and a larger equity base improve financial resilience and reduce the balance sheet burden associated with funding operations. This gives Luye greater flexibility to support product development, pursue commercialization opportunities, and absorb earnings volatility over the coming quarters.

Operating Cash Flow And Free Cash Flow Rebound

The return to positive operating and free cash flow indicates that the business can again convert operations into internally generated funding. Although consistency remains important, this rebound strengthens capacity to finance investment, service obligations, and support ongoing commercialization without relying solely on external capital.

Bears Say

Sharp Revenue Contraction

A steep revenue decline challenges the durability of demand and the scale of Luye’s current commercial platform. Even with strong margins, prolonged contraction can reduce operating leverage, limit reinvestment capacity, and make future earnings increasingly dependent on successful new products or market expansion.

Volatile Free Cash Flow Generation

Repeated periods of negative free cash flow and only moderate conversion in 2025 make cash returns less predictable than reported profitability. This variability can complicate long-term capital allocation, reduce financial flexibility during weaker sales periods, and limit confidence in consistently funding growth internally.

Low Return On Equity

A low return on equity suggests that the enlarged capital base is not yet producing strong bottom-line efficiency. Unless profitability improves relative to equity, Luye may generate limited shareholder returns from retained capital, while management faces pressure to deploy assets more productively.

Luye Pharma Group News

2186 FAQ

What was Luye Pharma Group’s price range in the past 12 months?
Luye Pharma Group lowest stock price was HK$1.55 and its highest was HK$3.25 in the past 12 months.
What is Luye Pharma Group’s market cap?
Luye Pharma Group’s market cap is HK$6.60B.
When is Luye Pharma Group’s upcoming earnings report date?
Luye Pharma Group’s next earnings report is estimated for Mar 31, 2027 (not yet confirmed), which is in 139 days.
How were Luye Pharma Group’s earnings last quarter?
Luye Pharma Group released its earnings results on Aug 30, 2026. The company reported HK$0.03 earnings per share for the quarter, missing the consensus estimate of HK$0.059 by -HK$0.028.
Is Luye Pharma Group overvalued?
According to Wall Street analysts Luye Pharma Group’s price is currently Undervalued.
Does Luye Pharma Group pay dividends?
Luye Pharma Group pays an annual dividend of HK$0.06 which represents an annual dividend yield of ―. See more information on Luye Pharma Group dividends here
What is Luye Pharma Group’s EPS estimate?
Luye Pharma Group’s EPS estimate is 0.07.
How many shares outstanding does Luye Pharma Group have?
Luye Pharma Group has 3,994,515,900 shares outstanding.
What happened to Luye Pharma Group’s price movement after its last earnings report?
Luye Pharma Group reported an EPS of HK$0.03 in its last earnings report, missing expectations of HK$0.059. Following the earnings report the stock price went up 3.719%.
Which hedge fund is a major shareholder of Luye Pharma Group?
Currently, no hedge funds are holding shares in HK:2186
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology